Main Article Content
Metastatic esophageal carcinoma is considered one of the worst prognosis cancersworldwide. The goals of treatment are usually symptoms palliation and possible lifeprolongation. In recent years, the field of immuno-oncology has shown promising treatmentresults and caused a paradigm shift in many types of cancer, as the response is quitelong-lasting. Anti-programmed cell death 1 (anti PD-1) is one of the immuno-oncologydrugs which has been investigated in many types of cancer and currently has beenapproved to be used in melanoma, lung cancer, kidney cancer and bladder cancer. Wereport a case of metastatic esophageal squamous cell carcinoma which had been heavilypretreated but presented an almost complete response to the anti PD-1, pembrolizumab.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. National Cancer Institute (NIH): Surveillance, Epidemi ology, and End Results Program (SEER). SEER Cancer statistics review (CSR) 1975-2013. (Accessed July 9, 2016 at http://seer.cancer.gov/csr/1975_2013/browse_csr. php sectionSEL=8&pageSEL=sect_08_table.08.html).
3. Lagergren J, Bergstrom R, Lindgren A, et al. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000; 85:340-6.
4. Engel LS, Chow WH, Vaughan TL, et al. Population at tributable risks of esophageal and gastric cancer. J Natl Cancer Inst 2003;95:1404-13.
5. Freedman ND, Abnet CC, Leitzmann MF, et al. A pro- spective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:1424-33.
6. Vaughan TL, Davis S, Kristal A, et al. Obesity, alcohol, and tobacco as risk factors for cancers of esophagus and gastric cardia: adenocarcinoma versus squamous cell car- cinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85- 92.
7. Powell NB, Schechtman KB, Riley RW, et al. Sleepy driving: accidents and injury. Otolaryngol Head Neck Surg 2002;126:217-27.
8. Korman AJ, Peggs KS, Allison JP. Checkpoint blockage in cancer immunotherapy. Adv Immunol 2006;90:297- 339.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
11. Hodi FS, O’Day SJ, McDermott DF, et al. Improved sur- vival with ipilimumab in patients with metastatic mela- noma. N Engl J Med 2010;363:711-23.
12. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-28.
13. Le DT, Uram JN, Wang H, et al. PD-1 blockage in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20.
14. Doi T, Piha-Paul SA, Jalal SI, et al. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J Clin Oncol 34, 2016 (suppl 4S; abstr 7).
15. ClinicalTrials.gov: A service of the U.S. National Insti- tutes of Health. Study of Pembrolizumab (MK-3475) versus investigator‘s choice standard therapy for partici- pants with advanced esophageal/esophagogastric junction carcinoma that progressed after first-line therapy (MK- 3475-181/KEYNOTE-181) 2016. (Accessed July 9, 2016 at https://clinicaltrials.gov/ct2/show/NCT02564263).